FDA Approves Pill That Nearly Doubled Median Survival In Pancreatic Cancer Trial

The story
The U.S. Food and Drug Administration approved a first-in-class pill Wednesday for certain patients with metastatic pancreatic cancer after a Phase III trial found that the treatment nearly doubled median survival compared with standard chemotherapy. Rasonque, known generically as daraxonrasib, is approved for adults with metastatic pancreatic adenocarcinoma who have received at least one previous […]
The post FDA Approves Pill That Nearly Doubled Median Survival In Pancreatic Cancer Trial appeared first on Dallas Express.
Powered by Gab AI
The Story At A Glance
Reading this article now — analysis appears below
💡 AI analysis provides alternative perspectives on current events